28.02.2024 - Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update. Financial Highlights Total revenue for the fourth quarter 2023 was $69.8 .
- CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code -
- Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect.
- CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect and favorable safety profile -NASHVILLE, Tenn. (BUSINESS WIRE) Revance Therapeutics, Inc. (RVNC) today announced that.
Revance Therapeutics, Inc. , today announced that the company will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference, taking place February 7-8, 2024, in New.
– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy.
– Preliminary unaudited Q4 and full year 2023.